Irrelevant to the prospects of Norwood are the average APSEC entry price, top 20 shareholder shuffling, the fortunes of CYM and UNT and the animus of posters here.
Far more pressing is the question of whether or not Norwood has a product that can be translated into a neutral or even positive cash flow.
For the past decade the cash from capital raisings has been directed to the CEO, the board, Alto, Radium, a "strategy consultant", airlines, hotels and FTI Consulting.
Shareholders will be hoping for a trend reversal.
NOR Price at posting:
4.2¢ Sentiment: None Disclosure: Not Held
